Biased Allosteric Modulators Of Metabotropic Glutamate Receptors: Novel Therapeutic Targets For CNS Disorders
Funder
National Health and Medical Research Council
Funding Amount
$611,534.00
Summary
Metabotropic glutamate receptor 5 (mGlu5) is a major therapeutic target for depression and schizophrenia. The proposed studies will improve our understanding of how drug-like chemicals interact with mGlu5 and therefore change the activity of these receptors and in turn the activity of brain cells leading to therapeutic effectiveness. The research undertaken in this program will allow us to be smarter in developing new mGlu5 drugs that are both effective and have minimal side effects.
Purinergic P2X7 Receptor As A Target For Antidepressant Drug Discovery
Funder
National Health and Medical Research Council
Funding Amount
$567,760.00
Summary
Depression is the most common mental disease. Around one million Australian adults and 100,000 young people live with depression each year resulting in significant economic, social and personal costs. Despite multiple treatments of depression, there are still several serious unmet needs with most current antidepressants showing limited effectiveness. We have identified a novel protein in the brain that represents an innovative approach to providing a platform for antidepressant drug discovery.